Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)

• Status: Unknown status
• Trial end date: 2007-09-01

Summary

The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke.

• Phase: Phase 4

Details

• Lead Sponsor: City Hospitals Sunderland NHS Foundation Trust
• Collaborator: Takeda
• Treatments: Candesartan; Candesartan cilexetil